

Ref: FOI/GS/ID 5088

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

29 November 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Cancer treatment.

You asked:

*1. In the past 3 months, how many **mNSCLC** patients were treated with?*

Afatinib

Atezolizumab

Becacizumab

Ceritinib

Crizotinib

Erlotinib

Gefitinib

Nitendaninb

Nivolumab

Pembrolizumab

Pemetrexed

Ramucirumab

Metastatic hepatocellular carcinoma

2. In the past three months, how many patients were treated with?

Bevacizumab

Cisplatin

Doxorubicin

Everolimus

Lapatinib

Levatinib

Regorafenib

Sorafenib

Sunitinib

TACE

Other active systemic anti-cancer therapy

Metastatic Thyroid Cancer

3. In the past three months, how many patients were treated with?

Axitinib

Cabozantinib

Levatinib
Pazopanib
Sorafenib
Sunitinib
Vandetanib
Others

Trust response:

For newly diagnosed cancers in the time period:

In the past 3 months, how many **mNSCLC** patients were treated with:

Afatinib - 0
Atezolizumab - 1
Becacizumab - 0
Ceritinib - 0
Crizotinib - 0
Erlotinib - 0
Gefitinib - 0
Nitendaninb - 0
Nivolumab - 0
Pembrolizumab - 1
Pemetrexed - 0
Ramucirumab - 0

Metastatic hepatocellular carcinoma

In the past three months, how many patients were treated with:

Bevacizumab - 0
Cisplatin - 0
Doxorubicin - 0
Everolimus - 0
Lapatinib - 0
Levatinib - 0
Regorafenib - 0
Sorafenib - 0
Sunitinib - 0
TACE - 0
Other active systemic anti-cancer therapy - 0

Metastatic Thyroid Cancer

In the past three months, how many patients were treated with:

Axitinib - 0
Cabozantinib - 0
Levatinib - 0
Pazopanib - 0
Sorafenib - 0
Sunitinib - 0
Vandetanib - 0
Others - 0